Vir Biotechnology, Inc. (VIR) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to Veer Biotechnology's third quarter 2025 financial results and corporate update call. As a reminder, this conference call is being recorded. At this time, all participants are in a listen-only mode. After the speaker's remarks, there will be a question and answer session. I will now turn the call over to Jason O'Byrne, Chief Financial Officer. Please go ahead. Thank you and good afternoon. With me today are Dr. Marianne DeBacker, our Chief Executive Officer, and Dr. Mark Eisner, our Chief Medical Officer. Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. These risks and uncertainties and risks associated with our business are described in the company's reports filed with the Securities and Exchange Commission, including forms 10-K, 10-Q, and 8-K. I will now turn the call over to our CEO, Marianne DeBacker. Please go ahead. Good afternoon, everyone, and thank you for joining us for Vier Biotechnology's third quarter 2025 earnings call. Today's call will highlight the significant progress we've made and our clear path forward as an organization. We'll provide guidance on our VR5500 program timeline, discuss the upcoming Solstice data presentation, and highlight how our clinical execution this quarter positions us for the significant value-creating opportunities ahead. The third quarter has been marked by important achievements across both our hepatitis delta and T-cell engager programs...